Literature DB >> 15550520

Functional effects of C-type natriuretic peptide and nitric oxide are attenuated in hypertrophic myocytes from pressure-overloaded mouse hearts.

Jun Su1, Qihang Zhang, Jacob Moalem, James Tse, Peter M Scholz, Harvey R Weiss.   

Abstract

Increases in the myocardial level of cGMP usually exert negative inotropic effects in the mammalian hearts. We tested the hypothesis that the negative functional effects caused by nitric oxide (NO) or C-type natriuretic peptide (CNP) through cGMP would be blunted in hypertrophied cardiac myocytes. Contractile function, guanylyl cyclase activity, cGMP-dependent protein phosphorylation, and calcium transients were assessed in ventricular myocytes from aortic stenosis-induced hypertrophic and age-matched control mice. Basal percentage shortening was similar in control and hypertrophic myocytes. S-nitroso-N-acetyl-penicillamine (SNAP, an NO donor, 10(-6) and 10(-5) M) or CNP (10(-8) and 10(-7) M) reduced percentage shortening in both groups, but their effects were blunted in hypertrophic myocytes. Maximal rates of shortening and relaxation were depressed at the basal level, and both reagents had attenuated effects in hypertrophy. Similar results were also found after treatment with guanylin and carbon monoxide, other stimulators of particulate, and soluble guanylyl cyclase, respectively. Guanylyl cyclase activity was not significantly changed in hypertrophy. Addition of Rp-8-[(4-chlorophenyl)thio]-cGMPS triethylamine (an inhibitor of cGMP-dependent protein kinase, 5 x 10(-6) M) blocked SNAP or the effect of CNP in control mice but not in hypertrophy, indicating the cGMP-dependent kinase (PKG) may not mediate the actions of cGMP induced by NO or CNP in the hypertrophic state. Calcium transients after SNAP or CNP were not significantly changed in hypertrophy. These results suggest that in hypertrophied mice, diminished effects of NO or CNP on ventricular myocyte contraction are not due to changes in guanylyl cyclase activity. The data also indicated that PKG-mediated pathways were diminished in hypertrophied myocardium, contributing to blunted effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550520     DOI: 10.1152/ajpheart.00880.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  8 in total

1.  Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes.

Authors:  Tao Tan; Peter M Scholz; Harvey R Weiss
Journal:  Life Sci       Date:  2010-05-12       Impact factor: 5.037

Review 2.  Physiological and Pathophysiological Effects of C-Type Natriuretic Peptide on the Heart.

Authors:  Akihiro Yasoda
Journal:  Biology (Basel)       Date:  2022-06-14

3.  Chronic nitrates blunt the effects of not only nitric oxide but also natriuretic peptides in cardiac myocytes.

Authors:  Tao Tan; Qihang Zhang; Chukwuma Anyadike; Peter M Scholz; Harvey R Weiss
Journal:  Pharmacol Res       Date:  2007-03-31       Impact factor: 7.658

Review 4.  Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy.

Authors:  Ines Pagel-Langenickel; Jens Buttgereit; Michael Bader; Thomas H Langenickel
Journal:  J Mol Med (Berl)       Date:  2007-04-12       Impact factor: 4.599

5.  SERCA inhibition limits the functional effects of cyclic GMP in both control and hypertrophic cardiac myocytes.

Authors:  Qihang Zhang; Tomer Davidov; Harvey R Weiss; Peter M Scholz
Journal:  Pharmacology       Date:  2009-03-04       Impact factor: 2.547

Review 6.  The failing diabetic heart: focus on diastolic left ventricular dysfunction.

Authors:  Loek van Heerebeek; Aernout Somsen; Walter J Paulus
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

Review 7.  Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors.

Authors:  Artem Ovchinnikov; Alexandra Potekhina; Evgeny Belyavskiy; Fail Ageev
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-19

Review 8.  An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.

Authors:  Si Chen; Chen Yan
Journal:  Expert Opin Drug Discov       Date:  2020-09-21       Impact factor: 6.098

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.